News

A first patient has been dosed in a Phase 3 trial testing relacorilant as a possible treatment for Cushing’s syndrome, the investigative treatment’s maker, Corcept Therapeutics, announced a press release. The trial, called GRACE (NCT03697109), is enrolling up to 130 endogenous Cushing’s patients at clinical sites in the U.S., Canada and Europe.

Pre-surgery treatment of adrenocorticotropic hormone (ACTH)-independent Cushing’s syndrome with Metopirone (metyrapone) leads to effective and safe improvement of hormonal levels and clinical parameters, according to a new pilot study. The research, “Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective…

Pituitary tumor conditions, such as Cushing’s disease, have a substantial effect on patients’ work capabilities and health-related quality of life, researchers from The Netherlands reported. The study, “Work disability and its determinants in patients with pituitary tumor-related disease,” was published in the journal Pituitary. Pituitary tumors, like…